Program Description
As chronic lymphocytic leukemia (CLL) moves to targeted, chemotherapy-free care, community oncology pharmacists in medically integrated practices are now central to therapy selection, safe initiation, and long-term management. This program provides practical guidance on using fixed-duration venetoclax regimens, covalent and non-covalent BTK inhibitors, and CAR T-cell referral pathways while managing real-world challenges such as tumor lysis syndrome, cardiovascular risk, and drug interactions. The session also addresses the 2026 Medicare Part D and IRA changes, including maximum fair prices and the Medicare Transaction Facilitator, to help oncology pharmacies maintain access, manage reimbursement, and avoid negative margins in CLL care.Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 13, 2026
Expiration date: May 13, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Adapt clinical evidence, guidelines, and patient-specific considerations into frontline regimen selection for patients with chronic lymphocytic leukemia (CLL)
- Examine evidence-based strategies to optimize safety protocols, manage therapy-related toxicities, and enhance adherence support for patients receiving novel targeted therapies in relapsed/refractory CLL
- Customize Medicare Transaction Facilitator enrollment, data matching, and refund reconciliation workflows to avoid negative margins for dispensing entities when acquisition costs exceed the maximum fair prices
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here